Salbutamol Sulfate EP Impurity K (HCl Salt)
✓
100 % Datengenauigkeit
Wissenschaftlicher Support rund um die Uhr
⬡
0 % Toleranz bei der Produktqualität

Lagerstandorte

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

Salbutamol Sulfate EP Impurity K (HCl Salt)

● Auf Lager

Katalog-Nr.::VE0025659
CAS-Nr.::N/A
Summenformel::C13H19Cl2NO3
Molare Masse::308.20 g/mol

Zusätzliche Informationen zu

Parent drug

Salbutamol

IUPAC-Name

2-(tert-butylamino)-1-(3-chloro-4-hydroxy-5-(hydroxymethyl)phenyl)ethanone hydrochloride

Synonyme

N/A

SMILES

OCC1=C(O)C(Cl)=CC(C(CNC(C)(C)C)=O)=C1.Cl

InChI

InChI=1S/C13H18ClNO3.ClH/c1-13(2,3)15-6-11(17)8-4-9(7-16)12(18)10(14)5-8;/h4-5,15-16,18H,6-7H2,1-3H3;1H

Beschreibung

Salbutamol Sulfate EP Impurity K (HCl Salt) is a process-related degradation product observed in salbutamol sulfate manufacture and stability studies, requiring targeted analytical control to meet pharmacopoeial limits. Physicochemical characterization typically includes LC-MS, HPLC with validated impurity methods, and NMR to confirm structure and salt form. Its presence can indicate incomplete salt formation, oxidative or hydrolytic pathways, or side reactions during synthesis, affecting batch purity and impurity profiling. Risk-based control strategies involve qualification, validated cleaning, impurity-specific reference standards and validated limits aligned with ICH Q3A and Q3B expectations to ensure consistent pharmaceutical quality.

Angebot anfordern

„*“ zeigt erforderliche Felder an

Dieses Feld dient zur Validierung und sollte nicht verändert werden.
Products quotation
Name
Url